Tafamidis not recommended for transthyretin amyloidosis with cardiomyopathy

NICE's decision follows an unsuccessful appeal against the draft recommendations by the company, Cardiomyopathy UK and the British Society for Heart Failure.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in